m+Medelevator.RU
← Поиск публикаций
Journal of translational medicine · 2026

Effectiveness of ultrasound-guided pulsed radiofrequency of the stellate ganglion for pain management in painful blind eye: a prospective case series.

Название и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Sanatkar M, Haydar AA, Espahbodi E, Rafizadeh SM

Аннотация

BACKGROUND: Painful blind eye (PBE) is a debilitating condition with limited and often unsatisfactory treatment options. This study describes our clinical experience with ultrasound-guided pulsed radiofrequency (PRF) of the stellate ganglion for pain management in PBE patients.

METHODS: This prospective case series included 20 consecutive PBE patients with chronic pain unresponsive to initial medical management. All underwent ultrasound-guided PRF of the stellate ganglion after a positive diagnostic block. Pain severity was assessed using the Numerical Rating Scale (NRS) at baseline and at multiple follow-up points for up to one year. The primary outcome was the change in NRS score. Secondary outcomes included analgesic use and the need for further interventions.

RESULTS: The median NRS score significantly decreased from a baseline of 8.66 (IQR: 8.32-9.11) to 2.07 (IQR: 1.46-2.70) at one year (P < 0.0001). The need for analgesic medications was significantly reduced (P < 0.0001), and no patient required subsequent retrobulbar injections or surgical enucleation/evisceration. No major adverse events were reported.

CONCLUSIONS: In our experience, ultrasound-guided PRF of the stellate ganglion was a promising and well-tolerated, globe-sparing treatment for refractory pain in PBE. While these preliminary findings are encouraging, this was a small, uncontrolled case series. Therefore, the effectiveness of this technique requires confirmation in larger, controlled trials before it can be widely recommended.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты